| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2056* | 2021 |
| Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 93 | 2023 |
| Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients EJ Carr, M Wu, R Harvey, EC Wall, G Kelly, S Hussain, M Howell, ... The Lancet 398 (10305), 1038-1041, 2021 | 93 | 2021 |
| New strategies and perspectives on managing IgA nephropathy H Selvaskandan, CK Cheung, M Muto, J Barratt Clinical and experimental nephrology 23, 577-588, 2019 | 87 | 2019 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 77 | 2022 |
| Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms RE Billany, H Selvaskandan, SF Adenwalla, KL Hull, DS March, ... Kidney international 99 (6), 1492-1494, 2021 | 67 | 2021 |
| Monitoring immune responses in IgA nephropathy: biomarkers to guide management H Selvaskandan, S Shi, S Twaij, CK Cheung, J Barratt Frontiers in immunology 11, 572754, 2020 | 46 | 2020 |
| Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial BH Rovin, J Barratt, HJL Heerspink, CE Alpers, S Bieler, DW Chae, ... The Lancet 402 (10417), 2077-2090, 2023 | 45 | 2023 |
| Acoustic trauma slows AMPA receptor‐mediated EPSCs in the auditory brainstem, reducing GluA4 subunit expression as a mechanism to rescue binaural function N Pilati, DM Linley, H Selvaskandan, O Uchitel, MH Hennig, ... The Journal of physiology 594 (13), 3683-3703, 2016 | 38 | 2016 |
| Immunological drivers of IgA nephropathy: Exploring the mucosa–kidney link H Selvaskandan, J Barratt, CK Cheung International Journal of Immunogenetics 49 (1), 8-21, 2022 | 33 | 2022 |
| The exclusion of patients with CKD in prospectively registered interventional trials for COVID-19—a rapid review of international registry data R Major, H Selvaskandan, YM Makkeyah, K Hull, A Kuverji, ... Journal of the American Society of Nephrology 31 (10), 2250-2252, 2020 | 33 | 2020 |
| MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? H Selvaskandan, I Pawluczyk, J Barratt Clinical kidney journal 11 (1), 29-37, 2018 | 30 | 2018 |
| Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis H Selvaskandan, C Kay Cheung, J Dormer, D Wimbury, M Martinez, G Xu, ... Nephron 144 (9), 453-458, 2020 | 24 | 2020 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 23 | 2023 |
| IgA nephropathy: an overview of drug treatments in clinical trials H Selvaskandan, G Gonzalez-Martin, J Barratt, CK Cheung Expert Opinion on Investigational Drugs 31 (12), 1321-1338, 2022 | 17 | 2022 |
| Burnout and long COVID among the UK nephrology workforce: results from a national survey investigating the impact of COVID-19 on working lives H Selvaskandan, A Nimmo, M Savino, S Afuwape, S Brand, ... Clinical kidney journal 15 (3), 517-526, 2022 | 17 | 2022 |
| A pilot study to predict risk of IgA nephropathy progression based on miR-204 expression I Pawluczyk, M Nicholson, S Barbour, L Er, H Selvaskandan, JS Bhachu, ... Kidney international reports 6 (8), 2179-2188, 2021 | 16 | 2021 |
| Impact of the COVID-19 pandemic on training, morale and well-being among the UK renal workforce H Beckwith, A Nimmo, M Savino, H Selvaskandan, M Graham-Brown, ... Kidney international reports 6 (5), 1433-1436, 2021 | 13 | 2021 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 12 | 2023 |
| New insights into the pathogenesis and treatment strategies in IgA nephropathy K Scionti, K Molyneux, H Selvaskandan, J Barratt, CK Cheung Glomerular Diseases 2 (1), 15-29, 2022 | 12 | 2022 |
